{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:53:16Z","timestamp":1784919196218,"version":"3.55.0"},"reference-count":48,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:p><jats:bold>Background<\/jats:bold> Antibiotic lengths of therapy (LOT) vary widely, based on infection type, antibiotic regimen, and patient characteristics. Longer LOT are associated with increased risk of antibiotic resistance, adverse effects, and health care costs. There are increasing data\n supporting shorter LOT for many infections based on randomized, controlled trials (RCTs).  <jats:bold>Objective<\/jats:bold> To evaluate RCTs supporting shorter antibiotic LOT for common infections, with an emphasis on applying the data to older adults.  <jats:bold>Data Sources<\/jats:bold> A list of\n RCTs that evaluated shorter LOT for common infections was first gathered from the website of Brad Spellberg, MD, at &lt;ext-link ext-link-type=\"uri\" xlink:href=\"https:\/\/www.bradspellberg.com\/shorter-is-better\"&gt;https:\/\/www.bradspellberg.com\/shorter-is-better&lt;\/ext-link&gt;. The list was\n then verified through a PubMed search using the terms for each infection and LOT.  <jats:bold>Data Synthesis<\/jats:bold> Of the 28 identified RCTs, 27 supported shorter antibiotic LOT. These trials were categorized by disease states: complicated urinary tract infections including pyelonephritis\n (n = 9), community-acquired pneumonia (n = 6), hospital-acquired pneumonia\/ ventilator-associated pneumonia (n = 3), skin and soft tissue infections (n = 4), complicated intra-abdominal infections (n = 2), and gram-negative bacteremia (n = 3). The single incongruent trial was conducted on\n male patients with complicated urinary tract infections, and the results could be explained by a lower than usual dose of antibiotic utilized in the study.  <jats:bold>Discussion<\/jats:bold> Many RCTs have demonstrated the safety and efficacy of shorter antibiotic LOT for the disease states included\n in this review. Several of these trials enrolled older adults.  <jats:bold>Conclusion<\/jats:bold> There are sufficient data to support using shorter antibiotic LOT in older patients. Implementing this strategy can help pharmacists and other health care professionals optimize antibiotic use in\n older adults.<\/jats:p>","DOI":"10.4140\/tcp.n.2025.18","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:31:08Z","timestamp":1735878668000},"page":"18-31","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotic Length of Therapy: Is Shorter Better in Older Adults?"],"prefix":"10.4140","volume":"40","author":[{"given":"Alice N.","family":"Hemenway","sequence":"first","affiliation":[{"name":"1 University of Illinois Chicago College of Pharmacy, Rockford, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Patton","sequence":"additional","affiliation":[{"name":"1 University of Illinois Chicago College of Pharmacy, Rockford, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"3 Palm Beach Atlantic University Gregory School of Pharmacy, West Palm Beach, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18773\/austprescr.2019.001","article-title":"Del Mar CB. Optimal antimicrobial duration for common bacterial infections.","volume":"42","year":"2019","journal-title":"Australian Prescriber"},{"issue":"222 Suppl","key":"ref2","first-page":"S142","article-title":"Antimicrobial treatment duration in sepsis and serious infections","volume":"2","year":"2020","journal-title":"J Infect Dis"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmi.2022.08.024","article-title":"Short course antibiotics for common infections: what do we know and where do we go from here?","volume":"29","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"ref4","year":"2024","journal-title":"Core Elements of Antibiotic Stewardship for Nursing Homes"},{"key":"ref5","year":"2024","journal-title":"Core Elements of Hospital Antibiotic Stewardship Programs"},{"key":"ref6","year":"2024","journal-title":"Implementation of Antibiotic Stewardship Core Elements at Small and Critical Access Hospital"},{"key":"ref7","year":"2024","journal-title":"Core Elements of Outpatient Antibiotic Stewardship"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cmi.2022.07.025","article-title":"How to change the course: Practical aspects of implementing shorter is better","volume":"29","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"ref9","year":"2024","journal-title":"Shorter Is Better"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: A randomized clinical trial","volume":"326","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10096-017-2951-6","article-title":"Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial","volume":"36","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","year":"2017","journal-title":"BMC Medicine"},{"issue":"9840","key":"ref13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","year":"2008","journal-title":"Urology"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1185\/030079907X233340","article-title":"A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and\/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis","volume":"23","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","year":"2000","journal-title":"JAMA."},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0924-8579(95)00011-V","article-title":"A sequential study of intravenous and oral Fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections","volume":"6","year":"1995","journal-title":"Int J Antimicrob Agents."},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","year":"1988","journal-title":"Acta Med Scand"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/cid\/ciad070","article-title":"PROSTASHORT Study Group. Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a multicenter noninferiority double blind placebo-controlled, randomized clinical trial","volume":"76","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America.","volume":"50","journal-title":"Clin Infect Dis"},{"issue":"10280","key":"ref21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Pneumonia Short Treatment (PTC) Study Group. Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diagmicrobio.2013.11.008","article-title":"A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia","volume":"80","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7554","key":"ref24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","year":"2006","journal-title":"BMJ"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02561528","article-title":"Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome\u2014a randomized study","volume":"27","year":"1999","journal-title":"Infection"},{"key":"ref27","first-page":"2332","volume-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","year":"2020"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"ref29","first-page":"00418","article-title":"REGARD-VAP investigators. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial","volume":"2600","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"e41290","DOI":"10.1371\/journal.pone.0041290","article-title":"Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment","volume":"7","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"ref31","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","year":"2003","journal-title":"JAMA."},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2019.09.019","article-title":"Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial","volume":"26","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","year":"2014","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","year":"2013","journal-title":"JAMA."},{"issue":"15","key":"ref36","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","year":"2004","journal-title":"Arch Intern Med."},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.","volume":"59","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00134-018-5088-x","article-title":"DURAPOP trial group. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial","volume":"44","year":"2018","journal-title":"Intensive Care Med."},{"issue":"21","key":"ref39","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"STOP-IT trial investigators. Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The Surgical Infection Society revised guidelines on the management of intra-abdominal infection","volume":"18","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"SHORTEN trial team. Seven versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","year":"2022","journal-title":"Clin Microbiol Infect."},{"issue":"21","key":"ref42","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","year":"2020","journal-title":"JAMA."},{"issue":"7","key":"ref43","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Bacteremia duration study group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4140\/TCP.n.2023.452","article-title":"The essential role of senior care pharmacists in antimicrobial stewardship: an updated position statement on behalf of the American Society of Consultant Pharmacists and the Society of Infectious Diseases Pharmacists","volume":"38","year":"2023","journal-title":"Sr Care Pharm"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/jac\/dkae146","article-title":"Barriers to the implementation of antimicrobial stewardship programmes in long-term care facilities: a scoping review","volume":"79","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"ref47","year":"2024","journal-title":"Antimicrobial Stewardship Certificate Program"},{"key":"ref48","year":"2024","journal-title":"Antimicrobial Stewardship Training Programs"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000001\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:31:25Z","timestamp":1735878685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["2639-9636(20250101)40:1L.18;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.18","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}